G-CON: Spotlight on… Continuous Manufacturing
In this Spotlight on Continuous Manufacturing, G-Con explains how they have simplified the entire design/build/validate process via their prefabricated cleanroom infrastructure line...
List view / Grid view
In this Spotlight on Continuous Manufacturing, G-Con explains how they have simplified the entire design/build/validate process via their prefabricated cleanroom infrastructure line...
Welcome to European Pharmaceutical Review’s roundtable devoted to continuous manufacturing. We have brought together six industry experts to focus on how the contribution of continuous manufacturing technology is shaping the pharmaceutical sector and explain what factors are driving that change.
In this edition of our 'Guide to' series, five leading companies that provide outsourcing services explain how their portfolio meets current industry needs.
Welcome to European Pharmaceutical Review’s Spotlight on Continuous Manufacturing.
In this issue: LC-MS multi-attribute methods for the characterising and QC testing therapeutics, integrating data from Quality Control and Production to enable fast and informed decisions, and Solid-state NMR spectroscopy: using freeze drying to predict the stability of biological products.
There is global public health concern over the falsification of pharmaceutical products and the extent to which widespread distribution of substandard drugs has developed...
The global pharmaceutical industry has been expanding steadily at varying rates of regional growth; the pace of growth being relatively slow in the developed, matured markets but rapid in developing nations...
Environmental monitoring programmes are all about risk management. Use of risk management techniques and a thorough understanding of the processes in the laboratory can assist in identifying any problematic areas...
Postponement packaging, or late-stage customisation, is the supply chain practice of keeping a product in a standard format for as long as possible, only making it market specific – or even customer specific – at the moment demand arises.
The biotechnology industry is expected to increase the production of new biopharmaceuticals.1 Biopharmaceuticals require high-quality standards, high initial investments for approval and introduction into the market as well as continued investment in manufacturing.2,3
The investigation and development of new drugs is a time-consuming and rigorous process with many challenges. Every step and each new method is developed with the intention of bringing effective medicines to patients in the shortest possible time, while ensuring the highest possible level of safety. Good product design, as…
The particle size of Active Pharmaceutical Ingredients (API) has a significant effect on a drug product’s manufacturability and performance. With respect to manufacturability, particle size can affect compatibility, flowability and blend uniformity; with respect to product performance it can affect solubility, dissolution, and bioavailability.
As the UK prepares to withdraw from the EU on 29th March 2019 at 23:00, this article delivers a US perspective on what Brexit is likely to mean for pharmaceutical companies.
As part of EPR’s Women inspiring Pharma series, Jill Larsen, EVP & CHRO, Medidata Solutions, talks to Science Editor Dr Zara Kassam about addressing the clear challenges facing women in pharma, supporting STEM education initiatives and building crucial relationships...
Quality Assurance (QA) covers all aspects that could have an impact on the quality of prescribed pharmaceutical products. This article focuses on some of the Pharmaceutical Quality Systems in relation to QA of manufactured medicines.